# 510(k) Summary ALPHA Histoplasma Antigen EIA

This 510(k) summary is submitted in accordance with 21 CFR §807.92

Assigned 510(k) No.: K101407

# Owner:

Immuno-Mycologics, Inc.   
2700 Technology Place   
Norman, OK 73071   
Tel: 405-360-4669   
Fax: 405-364-1058   
Contact: Dr. Sean K. Bauman, President & CEO

# Prepared:

July 7, 2011

# Trade Name:

ALPHA Histoplasma Antigen EIA

Common Name:

Histoplasma Antigen EIA

Classification Name: None

# Regulation:

866.3320

# Predicate Device:

Bio-Rad's Platelia™ Aspergillus EIA, K060641

# Intended Use:

The ALPHA Histoplasma Antigen ElA is an immunoenzymatic sandwich microplate assay for the detection of Histoplasma antigens in urine samples.

The ALPHA Histoplasma Antigen EIA is a test which, when used in conjunction with other diagnostic procedures such as microbiological culture, histological examination of biopsy samples and radiographic evidence, can be used as an aid in the diagnosis of histoplasmosis.

# Device Description:

The ALPHA Histoplasma Antigen EIA is an immunoenzymatic sandwich microplate assay which detects Histoplasma antigens in urine. Rabbit anti-Histoplasma IgG antibodies bound to microwell plates are used as capture antibodies and biotinylated rabbit anti-Histoplasma IgG antibodies are used as detect antibodies.

The positive control is made of buffer spiked with Histoplasma capsulatum antigens and the negative control is buffer only. Standards are made of Histoplasma capsulatum antigens from culture filtrate. The kit contains the 100 Standard, 30 Standard, 10 Standard, and 2 Standard that are used to generate a sigmoid calibration curve using a four-parameter fit of the blanked absorbance values versus the assigned ElA Values. R-squared values must be greater than or equal to 0.990.

Urine samples are run untreated and undiluted. The samples are added to the microwells coated with the capture antibody and incubated. If the patient specimen contains Histoplasma antigens that are recognized by the capture antibody, those antigens wilbecome bound to the microwell. The wells are washed to remove unbound patient material and biotinylated detection antibody is added to the wells. If Histoplasma antigens are bound to the microwell by the capture antibody, then the detect antibody will also become bound to the microwell. The wells are then washed to remove any unbound detect antibody. For detection, biotinstreptavidin chemistry reagents including $3 , 3 ^ { \prime } , 5 , 5 ^ { \prime }$ tetramethybenzadine (TMB) and stop solution are used. Streptavidin conjugated to horseradish peroxidase (HRP) is added to the microwells. In the presence of the biotinylated detect antibody, streptavidin-HRP will become bound to the plate. The plate is then washed to remove any unbound streptavidin-HRP, and TMB substrate solution is added to the microwells. A blue color develops in the presence of the HRP enzyme. The reaction is stopped by the addition of a stop solution. The optical density (absorbance) is determined with a microplate reader at 450nm and 640nm or 450nm alone. ElA Units for specimens are calculated using a four-parameter curve-fit generated with the 4 standards supplied in the kit.

# Comparison with Predicate:

A comparison of the similarities and differences between the ALPHA Histoplasma Antigen EIA and the predicate device is presented in the table below (Table 1).

Table 1. Similarities and Differences between ALPHA Histoplasma ElA and Platelia Aspergillus ElA   

<table><tr><td colspan="3" rowspan="1">SIMILARITIESFeature          ALPHA Histoplasma Ag EIA Device           Platelia Aspergillus ElA K060641</td></tr><tr><td colspan="3" rowspan="1">282Intended Us</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Antigen detection</td><td colspan="1" rowspan="1">Antigen detection</td></tr><tr><td colspan="1" rowspan="1">Indication For Use</td><td colspan="1" rowspan="1">Aid in the diagnosis</td><td colspan="1" rowspan="1">Aid in the diagnosis</td></tr><tr><td colspan="3" rowspan="1">DevicDescription,</td></tr><tr><td colspan="1" rowspan="1">Assay Principle</td><td colspan="1" rowspan="1">EIA</td><td colspan="1" rowspan="1">EIA</td></tr><tr><td colspan="1" rowspan="1">Assaycomponents</td><td colspan="1" rowspan="1">96-well microplate coated antibody, wash buffer,positive control, negative control, enzyme conjugate,TMB substrate, stop solution</td><td colspan="1" rowspan="1">96-well microplate coated antibody, wash buffer,positive control, negative control, enzymeconjugate, TMB substrate, stop solution</td></tr><tr><td colspan="1" rowspan="1">DetectionChemistry</td><td colspan="1" rowspan="1">HRP +TMB</td><td colspan="1" rowspan="1">HRP + TMB</td></tr><tr><td colspan="1" rowspan="1">Controls/Standard</td><td colspan="1" rowspan="1">Antigen</td><td colspan="1" rowspan="1">Antigen</td></tr><tr><td colspan="1" rowspan="1">Instruments</td><td colspan="1" rowspan="1">none</td><td colspan="1" rowspan="1">none</td></tr><tr><td colspan="1" rowspan="1">Microplate</td><td colspan="1" rowspan="1">96-well microplate coated with antibody</td><td colspan="1" rowspan="1">96-well microplate coated with antibody</td></tr><tr><td colspan="1" rowspan="1">PerformanceCharacteristics</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Precision</td><td colspan="1" rowspan="1">Acceptable % CVs</td><td colspan="1" rowspan="1">Acceptable % CVs</td></tr><tr><td colspan="1" rowspan="1">Linearity</td><td colspan="1" rowspan="1">Not applicable</td><td colspan="1" rowspan="1">Not applicable</td></tr><tr><td colspan="1" rowspan="1">Specificity</td><td colspan="1" rowspan="1">Cross-reacts with other fungal organisms</td><td colspan="1" rowspan="1">Cross-reacts with other fungal organisms</td></tr></table>

<table><tr><td rowspan=1 colspan=3>DIFFERENCESFeature                   ALPHA Histoplasma Ag EIA Device                  Platelia Aspergillus ElA K060641</td></tr><tr><td rowspan=1 colspan=1>Intended</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Detection of Histoplasma antigen in urine samples</td><td rowspan=1 colspan=1>Detection of Aspergillus galactomannan antigen inadult and pediatric serum samples</td></tr><tr><td rowspan=1 colspan=1>Indication For Use</td><td rowspan=1 colspan=1>Aid in the diagnosis of histoplasmosis.</td><td rowspan=1 colspan=1>Aid in the diagnosis of invasive aspergillosis.</td></tr><tr><td rowspan=1 colspan=1>DeviceDescription</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Sample Matrix</td><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Histoplasma antigens</td><td rowspan=1 colspan=1>Aspergillus galactomannan</td></tr><tr><td rowspan=1 colspan=1>Output</td><td rowspan=1 colspan=1>&quot;EIA Units&quot; as determined from standard curve</td><td rowspan=1 colspan=1>&quot;Index&quot; as determined by OD of sample divided byCut-Off Control OD</td></tr><tr><td rowspan=1 colspan=1>DetectionAntibody</td><td rowspan=1 colspan=1>Biotinylated anti-Histoplasma polyclonal antibody</td><td rowspan=1 colspan=1>HRP-linked anti-Aspergillus monoclonal antibody</td></tr><tr><td rowspan=1 colspan=1>Microplate</td><td rowspan=1 colspan=1>96-well microplate coated with anti-Histoplasmapolyclonal antibody</td><td rowspan=1 colspan=1>96-well microplate coated with anti-Aspergillusmonoclonal antibody</td></tr><tr><td rowspan=1 colspan=1>Assay Time</td><td rowspan=1 colspan=1>~3 hours</td><td rowspan=1 colspan=1>~2 hours</td></tr><tr><td rowspan=1 colspan=1>PeriormanceCharacteristics</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Shelf life</td><td rowspan=1 colspan=1>1 year</td><td rowspan=1 colspan=1>Each kit component different</td></tr></table>

# Analytical Performance Summary

A.Urine Precision Studies

Three sites, a reference laboratory (RL) (Western US), a clinical laboratory (CL) (Upper MidWestern US), and IMMY (Central US), were used to assess the assay's reproducibility. The panel consisted of urine samples at five levels: negative, high negative $( C _ { 5 } ) _ { i }$ , cut-off $( C _ { 5 0 } )$ , low positive $\{ \mathsf { C } _ { 9 5 } \}$ , and moderately positive. At the reference laboratory and at IMMY, each sample was tested in triplicate over the course of 5 days, using multiple operators. At the clinical laboratory, each sample was tested in triplicate over the course of 3 days, using a single operator. Throughout the study, reagent lots and instrument calibrations were held constant. No runs were removed from analysis due to failed runs.

Variance was estimated by calculating the mean value of each sample, the standard deviation and percent Cv. The data was analyzed separately to evaluate any inter-assay, intra-assay, and inter-site variation. Overall, no major source of variability was identied. Intra-run, Inter-Run, and Inter-site percent CVs are within acceptable limits $( \leq 2 0 \% )$ ,with the exception of the negative urine and low negative urine samples, which is expected when testing beyond the limit of detection. A summary of the data is reported in the Tables 2-4 below.

Table 2. Intra-run Reproducibility Analysis   

<table><tr><td rowspan=1 colspan=2> </td><td rowspan=1 colspan=7>                                                                        1€545</td></tr><tr><td rowspan=12 colspan=5>Neg.Urine        C5IJoefo  Ave    0.010      0.064t egSD0.0030.001%CV26.5%1.8%co ce       I oo  Ave    0.006      0.071eaSD0.0030.002%CV50.0%2.9%Ave0.0070.062IJojeoεAa  SD     0.002      0.002%CV31.2%3.4%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Moderate</td><td rowspan=2 colspan=1>PositiveControl</td></tr><tr><td rowspan=1 colspan=1>C5</td><td rowspan=1 colspan=1>C50</td><td rowspan=1 colspan=1>C95</td><td rowspan=1 colspan=1>Urine</td></tr><tr><td rowspan=3 colspan=1>IJoefot eg</td><td rowspan=1 colspan=1>Ave</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>0.064</td><td rowspan=1 colspan=1>0.078</td><td rowspan=1 colspan=1>0.092</td><td rowspan=1 colspan=1>0.810</td><td rowspan=1 colspan=1>0.218</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.003</td><td rowspan=1 colspan=1>0.001</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>0.003</td><td rowspan=1 colspan=1>0.032</td><td rowspan=1 colspan=1>0.008</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>26.5%</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>3.4%</td></tr><tr><td rowspan=3 colspan=1>I ooea</td><td rowspan=1 colspan=1>Ave</td><td rowspan=1 colspan=1>0.006</td><td rowspan=1 colspan=1>0.071</td><td rowspan=1 colspan=1>0.088</td><td rowspan=1 colspan=1>0.108</td><td rowspan=1 colspan=1>0.900</td><td rowspan=1 colspan=1>0.246</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.003</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>0.003</td><td rowspan=1 colspan=1>0.003</td><td rowspan=1 colspan=1>0.032</td><td rowspan=1 colspan=1>0.004</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>50.0%</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>1.5%</td></tr><tr><td rowspan=3 colspan=1>IJojeoεAa</td><td rowspan=1 colspan=1>Ave</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>0.062</td><td rowspan=1 colspan=1>0.074</td><td rowspan=1 colspan=1>0.086</td><td rowspan=1 colspan=1>0.783</td><td rowspan=1 colspan=1>0.211</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>0.041</td><td rowspan=1 colspan=1>0.009</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>31.2%</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>8.1%</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>4.3%</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=15 colspan=1>Rateeeeo*</td><td rowspan=3 colspan=1>O</td><td rowspan=1 colspan=1>Ave</td><td rowspan=1 colspan=1>0.006</td><td rowspan=1 colspan=1>0.035</td><td rowspan=1 colspan=1>0.054</td><td rowspan=1 colspan=1>0.057</td><td rowspan=1 colspan=1>0.523</td><td rowspan=1 colspan=1>0.136</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.003</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>0.001</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>0.011</td><td rowspan=1 colspan=1>0.008</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>39.7%</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>11.3%</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>5.6%</td></tr><tr><td rowspan=3 colspan=1>2zheqaeee</td><td rowspan=1 colspan=1>Ave</td><td rowspan=1 colspan=1>-0.003</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>0.065</td><td rowspan=1 colspan=1>0.061</td><td rowspan=1 colspan=1>0.612</td><td rowspan=1 colspan=1>0.172</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.006</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>0.001</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>0.024</td><td rowspan=1 colspan=1>0.008</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>183%</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>4.9%</td></tr><tr><td rowspan=3 colspan=1>aO</td><td rowspan=1 colspan=1>Ave</td><td rowspan=1 colspan=1>0.011</td><td rowspan=1 colspan=1>0.048</td><td rowspan=1 colspan=1>0.072</td><td rowspan=1 colspan=1>0.064</td><td rowspan=1 colspan=1>0.642</td><td rowspan=1 colspan=1>0.182</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.001</td><td rowspan=1 colspan=1>0.003</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>0.078</td><td rowspan=1 colspan=1>0.007</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>9.1%</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>4.9%</td><td rowspan=1 colspan=1>13.5%</td><td rowspan=1 colspan=1>12.2%</td><td rowspan=1 colspan=1>3.9%</td></tr><tr><td rowspan=3 colspan=1>eacO</td><td rowspan=1 colspan=1>Ave</td><td rowspan=1 colspan=1>-0.001</td><td rowspan=1 colspan=1>0.045</td><td rowspan=1 colspan=1>0.071</td><td rowspan=1 colspan=1>0.077</td><td rowspan=1 colspan=1>0.654</td><td rowspan=1 colspan=1>0.195</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>0.003</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>0.018</td><td rowspan=1 colspan=1>0.005</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>766%</td><td rowspan=1 colspan=1>11.8%</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>9.1%</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>2.4%</td></tr><tr><td rowspan=3 colspan=1>Jorerado</td><td rowspan=1 colspan=1>Ave</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>0.061</td><td rowspan=1 colspan=1>0.069</td><td rowspan=1 colspan=1>0.620</td><td rowspan=1 colspan=1>0.142</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.001</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>0.015</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>0.031</td><td rowspan=1 colspan=1>0.011</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>17.3%</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>24.5%</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>8.0%</td></tr><tr><td rowspan=1 colspan=4></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Ave</td><td rowspan=1 colspan=1>0.012</td><td rowspan=1 colspan=1>0.049</td><td rowspan=1 colspan=1>0.070</td><td rowspan=1 colspan=1>0.081</td><td rowspan=1 colspan=1>0.686</td><td rowspan=1 colspan=1>0.204</td></tr></table>

<table><tr><td colspan="1" rowspan="6">t3</td><td colspan="1" rowspan="3">Toeadoi5</td><td colspan="1" rowspan="1">Ave</td><td colspan="1" rowspan="1">0.012</td><td colspan="1" rowspan="1">0.049</td><td colspan="1" rowspan="1">0.070</td><td colspan="1" rowspan="1">0.081</td><td colspan="1" rowspan="1">0.686</td><td colspan="1" rowspan="1">0.204</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">0.003</td><td colspan="1" rowspan="1">0.010</td><td colspan="1" rowspan="1">0.014</td><td colspan="1" rowspan="1">0.011</td><td colspan="1" rowspan="1">0.039</td><td colspan="1" rowspan="1">0.027</td></tr><tr><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">24.2%</td><td colspan="1" rowspan="1">20.6%</td><td colspan="1" rowspan="1">19.4%</td><td colspan="1" rowspan="1">13.6%</td><td colspan="1" rowspan="1">5.7%</td><td colspan="1" rowspan="1">13.0%</td></tr><tr><td colspan="1" rowspan="3">xyx^}$</td><td colspan="1" rowspan="1">Ave</td><td colspan="1" rowspan="1">0.004</td><td colspan="1" rowspan="1">0.039</td><td colspan="1" rowspan="1">0.068</td><td colspan="1" rowspan="1">0.066</td><td colspan="1" rowspan="1">0.623</td><td colspan="1" rowspan="1">0.226</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">0.002</td><td colspan="1" rowspan="1">0.002</td><td colspan="1" rowspan="1">0.010</td><td colspan="1" rowspan="1">0.005</td><td colspan="1" rowspan="1">0.043</td><td colspan="1" rowspan="1">0.028</td></tr><tr><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">57.1%</td><td colspan="1" rowspan="1">4.5%</td><td colspan="1" rowspan="1">15.1%</td><td colspan="1" rowspan="1">7.6%</td><td colspan="1" rowspan="1">6.8%</td><td colspan="1" rowspan="1">12.5%</td></tr><tr><td colspan="1" rowspan="9">MNR*!. *1V:35</td><td colspan="1" rowspan="3">EAaI JooE.</td><td colspan="1" rowspan="1">Ave</td><td colspan="1" rowspan="1">0.003</td><td colspan="1" rowspan="1">0.045</td><td colspan="1" rowspan="1">0.067</td><td colspan="1" rowspan="1">0.076</td><td colspan="1" rowspan="1">0.723</td><td colspan="1" rowspan="1">0.216</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">0.001</td><td colspan="1" rowspan="1">0.006</td><td colspan="1" rowspan="1">0.009</td><td colspan="1" rowspan="1">0.004</td><td colspan="1" rowspan="1">0.051</td><td colspan="1" rowspan="1">0.004</td></tr><tr><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">36.4%</td><td colspan="1" rowspan="1">13.6%</td><td colspan="1" rowspan="1">13.3%</td><td colspan="1" rowspan="1">5.3%</td><td colspan="1" rowspan="1">7.0%</td><td colspan="1" rowspan="1">1.6%</td></tr><tr><td colspan="1" rowspan="3">¥7.</td><td colspan="1" rowspan="1">Ave</td><td colspan="1" rowspan="1">0.008</td><td colspan="1" rowspan="1">0.043</td><td colspan="1" rowspan="1">0.064</td><td colspan="1" rowspan="1">0.068</td><td colspan="1" rowspan="1">0.653</td><td colspan="1" rowspan="1">0.202</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">0.003</td><td colspan="1" rowspan="1">0.006</td><td colspan="1" rowspan="1">0.009</td><td colspan="1" rowspan="1">0.006</td><td colspan="1" rowspan="1">0.025</td><td colspan="1" rowspan="1">0.017</td></tr><tr><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">38.6%</td><td colspan="1" rowspan="1">15.1%</td><td colspan="1" rowspan="1">14.7%</td><td colspan="1" rowspan="1">8.1%</td><td colspan="1" rowspan="1">3.8%</td><td colspan="1" rowspan="1">8.4%</td></tr><tr><td colspan="1" rowspan="3">Zod</td><td colspan="1" rowspan="1">Ave</td><td colspan="1" rowspan="1">0.005</td><td colspan="1" rowspan="1">0.042</td><td colspan="1" rowspan="1">0.072</td><td colspan="1" rowspan="1">0.080</td><td colspan="1" rowspan="1">0.663</td><td colspan="1" rowspan="1">0.228</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">0.002</td><td colspan="1" rowspan="1">0.005</td><td colspan="1" rowspan="1">0.008</td><td colspan="1" rowspan="1">0.008</td><td colspan="1" rowspan="1">0.034</td><td colspan="1" rowspan="1">0.006</td></tr><tr><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">31.6%</td><td colspan="1" rowspan="1">12.2%</td><td colspan="1" rowspan="1">11.3%</td><td colspan="1" rowspan="1">10.3%</td><td colspan="1" rowspan="1">5.1%</td><td colspan="1" rowspan="1">2.7%</td></tr></table>

Table 3. Inter-Run Reproducibility Analysis   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=7>inter-Run Analysis-BlankedoD Values</td></tr><tr><td rowspan=4 colspan=8>Neg.                                        ModeratePositiveUrine      C5       C50      C95      Urine    ControlAve     0.008    0.066    0.080    0.095     0.831    0.225Std. Dev.   0.003    0.005    0.007    0.011     0.061     0.017% CV     38.7%    7.0%     8.6%    11.0%     7.4%     7.6%</td></tr><tr><td rowspan=1 colspan=1>Ave</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>0.066</td><td rowspan=1 colspan=1>0.080</td><td rowspan=1 colspan=1>0.095</td><td rowspan=1 colspan=1>0.831</td><td rowspan=1 colspan=1>0.225</td></tr><tr><td rowspan=1 colspan=1>Std. Dev.</td><td rowspan=1 colspan=1>0.003</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>0.011</td><td rowspan=1 colspan=1>0.061</td><td rowspan=1 colspan=1>0.017</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>38.7%</td><td rowspan=1 colspan=1>7.0%</td><td rowspan=1 colspan=1>8.6%</td><td rowspan=1 colspan=1>11.0%</td><td rowspan=1 colspan=1>7.4%</td><td rowspan=1 colspan=1>7.6%</td></tr><tr><td rowspan=3 colspan=1>ReferenceLaboratony3</td><td rowspan=1 colspan=1>Ave</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>0.064</td><td rowspan=1 colspan=1>0.066</td><td rowspan=1 colspan=1>0.610</td><td rowspan=1 colspan=1>0.165</td></tr><tr><td rowspan=1 colspan=1>Std. Dev.</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>0.059</td><td rowspan=1 colspan=1>0.025</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>187.0%</td><td rowspan=1 colspan=1>12.7%</td><td rowspan=1 colspan=1>13.9%</td><td rowspan=1 colspan=1>13.1%</td><td rowspan=1 colspan=1>9.6%</td><td rowspan=1 colspan=1>14.9%</td></tr><tr><td rowspan=3 colspan=1>bos.4IMY</td><td rowspan=1 colspan=1>Ave</td><td rowspan=1 colspan=1>0.006</td><td rowspan=1 colspan=1>0.043</td><td rowspan=1 colspan=1>0.068</td><td rowspan=1 colspan=1>0.074</td><td rowspan=1 colspan=1>0.670</td><td rowspan=1 colspan=1>0.215</td></tr><tr><td rowspan=1 colspan=1>Std. Dev.</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>0.006</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>0.048</td><td rowspan=1 colspan=1>0.020</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>64.2%</td><td rowspan=1 colspan=1>14.9%</td><td rowspan=1 colspan=1>13.2%</td><td rowspan=1 colspan=1>11.7%</td><td rowspan=1 colspan=1>7.2%</td><td rowspan=1 colspan=1>9.1%</td></tr></table>

Table 4. inter-Site Reproducibility Analysis   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=7>Inter-Site Analysis - Blanked OD Values. </td></tr><tr><td rowspan=1 colspan=7>Neg.                                         ModerateUrine      CS       C50       C95       Urine</td><td rowspan=1 colspan=1>PositiveControl</td></tr><tr><td rowspan=3 colspan=1></td><td rowspan=1 colspan=1>Ave</td><td rowspan=1 colspan=1>0.006</td><td rowspan=1 colspan=1>0.048</td><td rowspan=1 colspan=1>0.069</td><td rowspan=1 colspan=1>0.076</td><td rowspan=1 colspan=1>0.684</td><td rowspan=1 colspan=1>0.198</td></tr><tr><td rowspan=1 colspan=1>Std. Dev.</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>0.011</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>0.014</td><td rowspan=1 colspan=1>0.101</td><td rowspan=1 colspan=1>0.034</td></tr><tr><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>95.9%</td><td rowspan=1 colspan=1>23.7%</td><td rowspan=1 colspan=1>14.8%</td><td rowspan=1 colspan=1>19.1%</td><td rowspan=1 colspan=1>14.8%</td><td rowspan=1 colspan=1>17.0%</td></tr></table>

BAnalytical Sensitivity (Lower limits of the assay) Analytical sensitivity was determined (according to CLSi EP17-A) by determining the assay's Limit of the Blank and Limit of Detection. Wash buffer was spiked with Histoplasma antigens at a concentration range of 1 - 4 ElA Units. To determine the LoB, 82 replicates of wash buffer were assayed. To determine the LoD, 30 replicates of the spiked wash buffer were assayed. The Limit of the Blank is 0.009 OD and the Limit of Detection is 2 ElA Units (0.044 Blanked OD).

C. Analytical Specificity (Cross-Reactivity)

Urine specimens that tested negative for Histoplasma antigen were spiked with antigen from Blastomyces dermatitidis, Coccidioides immitis, Aspergillus sp., Paracoccidioides brasilliensis, Candida albicans, and Cryptococcus neoformans, individually at 1ug/ml. The ALPHA Histoplasma Antigen ElA is found to be cross-reactive with Blastomyces dermatitidis, Coccidioides immitis, and Paracoccidioides brasilliensis. The assay is not cross-reactive with Candida albicans, Cryptococcus neoformans, or Aspergillus sp. in urine. Furthermore, Aspergillus, Candida, Paracoccidioides, and Penicillium culture-positive urine specimens were tested in the ALPHA Histoplasma Antigen ElA. The results are summarized in Table 5.

Table 5. Specificity Using Culture-Confirmed Urine Specimens   

<table><tr><td rowspan="5">Aspergillus Candida spp.</td><td>Percent Positive</td></tr><tr><td>0% (0/20)</td></tr><tr><td>0% (0/12)</td></tr><tr><td>Paracoccidioides 9.1% (1/11)</td></tr><tr><td>0% (0/2)</td></tr></table>

# D.Analytical Interference

To evaluate substances that could potentially interfere with the ALPHA Histoplasma Antigen ElA, urine specimens containing various substances were obtained from a national reference laboratory. Substances included protein, blood, epithelial cells, ketones, mucus, casts, glucose, and bilirubin. Each specimen was spiked with Histoplasma antigen and tested. None of these substances were found to interfere with the ALPHA Histoplasma Antigen ElA. Vaginal cream urines and foods which produce color in urine were not tested. Additionally, drugs, such as itraconazole, amphotericin B, acetaminophen, acetylsalicylic acid, ascorbic acid, and caffeine were not tested for interference.

# E. Carry-over

To examine potential well-to-well carry-over, a positive sample was used in series alternating with a negative sample in a checkerboard pattern. Samples were found not to carry-over when methods described in the package insert were followed.

F. Prozone Effect

To detect the prozone effect in the ALPHA Histoplasma Antigen ElA, negative urine was spiked with Histoplasma antigen to 2000, 3000, and 4000 EIA Units and tested. All samples remained positive, therefore, prozoning is not seen in the ALPHA Histoplasma Antigen EIA.

G. Linearity

N/A

H.Assay cut-off

The assay's cut-off of 2.0 ElA Units was established by Limit of Detection (Section B) experiments and confirmed with the determination of the ${ \mathsf { C } } _ { 5 0 }$ Receiver Operator Curve (ROC) analysis of cuiture-proven specimens indicated a 1.3 EIA Unit cutoff. However, this is below the Limit of Detection (2.0 ElA units), and therefore an inappropriate cutoff.

Negative: < 2.0 EIA Units Positive: $\geq 2 . 0$ EMPY

# I.Single Versus Dual Wavelength Analysis

Eight positive urine samples and the 4 standards were tested in duplicate and according to the package insert. The microwells were read at $4 5 0 / 6 3 0 \ : \mathsf { n m }$ and then at $4 5 0 n m$ only. The study confirmed that the blanked OD of a sample is not affected by the read method, as indicated by the low percent CVs across both read methods. Furthermore, 450/630 vs. 450 alone can be used with equal accuracy, and data from the two methods can be used interchangeably.

# J. Reading the Test

To demonstrate that the test should be read within 15 minutes after the addition of the Stop Solution, all the standards were run in triplicate according to the package insert. The test was then read immediately after the addition of the Stop Solution, and then at 15, 30, 45, 60, 75, and 90 minutes. The signal began to decrease after 15 minutes and continued to decrease over the course of 90 minutes. While the decrease was not significant, it is still preferable to read the assay as soon after the addition of the Stop Solution as possible to avoid errors.

# K. Specimen Acceptance Criteria

In specimen storage studies, reductions in ElA values after 2-week storage at $4 \%$ and after multiple freeze thaws were observed. However, no specimen went from positive to negative (Figures 1 and 2). Since a reduction in ElA values was observed, it is possible that a fresh, very low-positive specimen (near 2.0 ElA units) could become negative if it is stored for several days.

![](images/e1971acab17d4a73d1fe848c523745c0c7e36d6a84212be3035f7e0982f42daa.jpg)  
Figure 1. ElA Units Versus Days Stored at 4°C

![](images/538820c64abb74a2828024c2995a0db4657cff432707d831963dc2bff62f039c.jpg)  
Figure 2. ElA Units Versus Days Stored at $- 2 0 ^ { \circ } C$

# L. Method Comparison

# Comparison to Culture/Histopathology:

The clinical performance of the ALPHA Histoplasma Antigen ElA was evaluated using a total of 278 culture- or histopathology-confirmed urine specimens. The results are summarized in Tables 6 and 7.

Table 6. 2x2 Contingency Table Comparing Device to Culture/Histopathology   

<table><tr><td colspan="3">Culture/Histopathology</td></tr><tr><td rowspan="2">IMMY ALPHA Positive</td><td>Positive</td><td>Negative</td></tr><tr><td>38</td><td>3</td></tr><tr><td>Histoplasma EIA Negative</td><td>9</td><td>228</td></tr></table>

Statalnaly vi Culu/Histoa   

<table><tr><td colspan="3">Point</td></tr><tr><td rowspan="2">Sensitivity Specificity</td><td>Estimate 80.9%</td><td>95% CI 67.5-89.6%</td></tr><tr><td>98.7%</td><td>96.3-99.6%</td></tr></table>

# Comparison to Other Histoplasma Antigen ElA

Supplemental comparison studies were performed using a non-FDA-cleared Histoplasma capsulatum quantitative antigen ElA. The other test has an equivocal range and therefore, analysis was performed by either considering the equivocals positive or negative. The resulting 2x2 contingency tables (Tables 8 and 10) and statistical analysis (Tables 9 and 11) are below.

Table 8. 2x2 Contingency Table Comparing Device to other EA; Equivocals Assumed Positive   

<table><tr><td colspan="3">Other Histo Antigen EIA</td></tr><tr><td rowspan="2">IMMY ALPHA Positive</td><td>Positive</td><td>Negative</td></tr><tr><td>35</td><td>3</td></tr><tr><td>Histoplasma EIA</td><td>Negative</td><td>14</td><td>47</td></tr></table>

Table 9. Statistical Analysis   

<table><tr><td colspan="3">Point Estimate</td></tr><tr><td rowspan="2">% Agree Positive % Agree Negative</td><td>71.4%</td><td>95% CI 57.6-82.2%</td></tr><tr><td>94.0%</td><td>83.8-97.9%</td></tr></table>

<table><tr><td colspan="3">Other Histo Antigen EIA</td></tr><tr><td rowspan="2">IMMY ALPHA Positive</td><td>Positive</td><td>Negative</td></tr><tr><td>35</td><td>3</td></tr><tr><td>Histoplasma EIA Negative</td><td>3</td><td>58</td></tr></table>

Table 10. 2x2 Contingency Table Comparing Device to other ElA; Equivocals Assumed Negative

Table 11. Statistical Analysis   

<table><tr><td colspan="3">Point</td></tr><tr><td rowspan="2">% Agree Positive % Agree Negative</td><td>Estimate 92.1%</td><td>95% CI 79.2-97.3%</td></tr><tr><td>95.1%</td><td>86.5-98.3%</td></tr></table>

# Conclusion

The information submitted in this premarket notification is complete and supports a substantial equivalence decision.

Immuno-Mycologics, Inc c/o Sean K. Bauman, Ph.D. President and CEO 2700 Technology Place Norman, OK 73071

JUL 19 2011

Re: k101407 Trade/Device Name: ALPHA Histoplasma Antigen EIA Regulation Number: 21CFR $\ S 8 6 6 . 3 3 2 0$ EPY Regulation Name: Histoplasma capsulatum serological reagents. Regulatory Class: Class II Product Code: MIZ Dated: July 11, 2011 Received: July 12, 2011

Dear Dr. Bauman:

We have reviewed your Section $5 1 0 ( \boldsymbol { \mathbf { k } } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050. This letter will allow you to begin marketing your device as described in your Section

Page 2 - Sean K. Bauman, Ph.D.

510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http:/www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/dd91ce7626e6e4c39c92a149f823ce6b6ea5b0c048abf2d942877e4ef41f3d60.jpg)

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use Statement

510(k) Number (if known): K101407

Device Name: ALPHA Histoplasma Antigen EIA

Indications for Use:

The ALPHA Histoplasma Antigen EIA is an immunoenzymatic sandwich microplate assay for the detection of Histoplasma antigens in urine samples.

The ALPHA Histoplasma Antigen ElA is a test which, when used in conjunction with other diagnostic procedures such as microbiological culture, histological examination of biopsy samples and radiographic evidence, can be used as an aid in the diagnosis of histoplasmosis.

# Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k): K101407